Novo Nordisk knocks out Fresenius, DaVita and Baxter

Novo ‘s announcement sent Fresenius Medical Care shares down 16%. In JPMorgan’s view, there could not have been a worse announcement for the German group. FLOW, the name of the Danish company’s study, evaluated the efficacy of semaglutide (Ozempic) in slowing the progression of chronic kidney diseas…
© MarketScreener.com 2023